RxDoctor Payments Data

Jie Liu

Internal Medicine · Marietta, GANPI 1396972402

Payments from drug & device makers

$7,583in general payments, 2019–2025

Across 387 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$851
  • AbbVie$753
  • Amgen$747
  • AstraZeneca$662
  • Astellas Pharma US Inc$628
  • Pfizer$494
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$7,37797%
  • Education$2063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,583 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$122,896
Medicare patients
401
Services billed
1,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$127,357
JardianceEmpagliflozin60$89,183
EliquisApixaban77$72,670
MounjaroTirzepatide44$51,018
Tresiba Flextouch U-200Insulin Degludec35$32,618
JanuviaSitagliptin Phosphate24$29,989
MyrbetriqMirabegron27$29,169
FarxigaDapagliflozin Propanediol11$14,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,764
PremarinEstrogens, Conjugated16$8,125
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$7,497
SynthroidLevothyroxine Sodium95$6,949
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$6,059
Combivent RespimatIpratropium/Albuterol Sulfate12$5,779
Humalog Kwikpen U-100Insulin Lispro17$5,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$851$127,357127 claims
Boehringer IngelheimJardiance, Combivent Respimat$139$94,96272 claims
PfizerEliquis, Premarin$494$80,79593 claims
Lilly USA, LLCMounjaro$331$51,01844 claims
MerckJanuvia$85$29,98924 claims
Astellas Pharma US IncMyrbetriq$628$29,16927 claims
AstraZenecaFarxiga$662$14,96711 claims
GSKTrelegy Ellipta$189$12,76419 claims
AbbVieSynthroid$753$6,94995 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$4,445484 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →